Diagnosing NICTH necessitates a comprehensive approach that considers the patient's initial symptoms, tumor type, and recurrent hypoglycemia in the absence of organ damage, hormonal deficiencies, or medication-induced hypoglycemia. Laboratory findings will typically demonstrate low glucose levels concurrent with decreased levels of insulin, proinsulin, C-peptide, and β-hydroxybutyrate. This evidence concerns the gene INS and neoplasm.